3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
12
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Breast Carcinoma In Situ
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
Bevacizumab
19
Paclitaxel
16
Carboplatin
12
pembrolizumab
11
liposomal doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Gemcitabine
8
olaparib
7
fludarabine
7
Topotecan
7
Magnetic Resonance Spectroscopy
7
Taxes
5
Immunoglobulin G
5
Fulvestrant
5
Disulfides
5
niraparib
4
Oxaliplatin
4
Nivolumab
4
Biopsy
4
trastuzumab deruxtecan
3
palbociclib
3
mirvetuximab soravtansine
3
aldesleukin
3
Leucovorin
3
Fluorouracil
3
1-dodecylpyridoxal
3
ulixertinib
2
nilotinib
2
ipatasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
exemestane
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled